Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.

In May 2024, Pfizer said it is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All." 

In August 2024, Pfizer introduced the PfizerForAll digital platform in collaboration with UpScriptHealth, Alto Pharmacy, and Instacart.

The move, as reflected in a recent trademark application, aims to provide medical information, mail-order pharmacy services, and telehealth services to US patients.

The offering provides an opportunity for uninsured, underinsured, or self-pay patients to lower their out-of-pocket costs.

Beginning Sept. 8, eligible U.S. patients with an Eliquis prescription may purchase the medicine directly through Eliquis 360 Support. They will pay a discounted rate ...